Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14255MR)

This product GTTS-WQ14255MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ14255MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9478MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IPH-5401
GTTS-WQ15035MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SRF-231
GTTS-WQ7443MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GBR500
GTTS-WQ9361MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ7780MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ13993MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ4235MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ9895MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA KB001-A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW